US 12,692,287 B2Granted

Polymorphic form of reduced B-nicotinamide mononucleotide calcium salt, and preparation method and use therefor

AssigneeEffepharm (Shanghai) Co., Ltd.

InventorsXing Gao, Jianjun Yu, Qiang Shen, Qinyuan Xu, Yunkang Ding, Debin Ling, Lulu Xuan, Yang Li, Jialing Liu

Life of this patent

Estimating the term…

Loading patent…

Abstract

A compound NMNH calcium salt, in particular a polymorph of a reduced β-nicotinamide mononucleotide calcium salt and a preparation method therefor, a use thereof as a pharmaceutical ingredient, a health care product ingredient and a cosmetic ingredient or as a food additive, and a formulation containing same, belonging to the field of medicines, health care products, cosmetics and food additives. For the NMNH calcium salt polymorph, the crystal thereof displays long-term continuous stability, and compared with NMNH disodium salt, has significantly superior stability performance and anti-hygroscopic properties, and is more beneficial to long-term storage, promotion and market application. The NMNH calcium salt crystal is simple in preparation process, easy to control and suitable for large-scale production.

Claims28

Dependent claims

A crystalline calcium salt of a reduced ß-nicotinamide mononucleotide, wherein the crystalline calcium salt has a structure of Formula (I),

and wherein the crystalline calcium salt has an X-ray powder diffraction (XRPD) pattern having peaks at one of the following:
(a) at least three 2θ values selected from the group consisting of:
6.9°±0.2°, 9.5°±0.2°, 12.6°±0.2°, 15.6°±0.2°, 17.9°±0.2°, 21.0°±0.2°, 21.8°±0.2°, and 25.4°±0.2°;
(b) at least three 2θ values selected from the group consisting of:
6.5°±0.2°, 8.1°±0.2°, 11.9°±0.2°, 13.1°±0.2°, 17.6°±0.2°, 21.4°±0.2°, 23.7°±0.2°, and 26.9°±0.2°;
(c) at least three 2θ values selected from the group consisting of:
6.2°±0.2°, 9.7°±0.2°, 12.4°±0.2°, 16.1°±0.2°, 17.1°±0.2°, 18.7°±0.2°, 20.8°±0.2°, and 26.6°±0.2°;
(d) at least three 2θ values selected from the group consisting of:
7.0°±0.2°, 8.0°±0.2°, 12.0°±0.2°, 17.8°±0.2°, 20.2°±0.2°, 26.9°±0.2°;
or
(e) at least three 2θ values selected from the group consisting of:
6.9°±0.2°, 8.0°±0.2°, 11.9°±0.2°, 17.8°±0.2°, 20.2°±0.2°, 26.9°±0.2°.

9 more elements

A crystalline calcium salt of a reduced β-nicotinamide mononucleotide, wherein the crystalline calcium salt has a structure of Formula (I),

wherein the crystalline calcium salt comprises a crystalline form selected from the group consisting of crystalline form A, crystalline form B, crystalline form C, crystalline form D, and crystalline form E,
wherein
the crystalline form A exhibits an XRPD pattern of FIG. 1;
the crystalline form B exhibits an XRPD pattern of FIG. 2;
the crystalline form C exhibits an XRPD pattern of FIG. 3;
the crystalline form D exhibits an XRPD pattern of FIG. 4;
and
the crystalline form E exhibits an XRPD pattern of FIG. 5.

5 more elements

Dependencies are inferred from the claim text.